Chest
Gold-Naproxen Pneumonitis: A Toxic Drug Interaction?
Section snippets
Case Report
A 62 year-old man developed seropositive RA in 1984 and was treated with various NSAIDs. Chrysotherapy was initiated in May 1986 and he received a total of 685 mg SATM over three months when the drug had to be discontinued because of mucodermatitis. Naproxen, 500 mg twice daily, had been started in July 1986. About this time, he began to complain of malaise, fatigue, anorexia, and a nocturnal cough. Over the next four weeks, his cough became continuous, he developed mild dyspnea and chest
In Vitro Studies
In an effort to determine the etiology of what appeared to be a hypersensitivity pneumonitis, in vitro studies thought to be relatively predictive of cell-mediated immunity to pharmacologic agents were performed.10, 11, 12, 13 Briefly, PBMC, harvested from Ficoll-Hypaque cushions were obtained from the patient and three healthy male volunteers. The PBMC from the patient were cultured in the presence of media alone (control), mitogen (1 percent PHA), and various concentrations of naproxen and
DISCUSSION
Previous investigators have demonstrated an inhibitory effect of various gold salts on the cell-mediated immune response in vitro,14, 15, 16, 17 compatible with its role as an immunosuppressive agent in RA patients. We have also demonstrated that SATM inhibits the in vitro proliferation of mitogen treated cells from healthy subjects, and have also shown that naproxen may have additional immunosuppressive effects when used in combination with SATM (Fig 1). In contrast, cells from our patient
REFERENCES (19)
- et al.
Reversal of progressive, life-threatening gold hypersensitivity pneumonitis by corticosteroids.
Am J Med
(1981) - et al.
Pulmonary infiltrates with eosinophilia due to naproxen.
Chest
(1983) Lymphocyte transformation in drug hypersensitivity.
Lancet
(1967)Immunologic effects of nonsteroidal anti-inflammatory drugs.
Am J Med
(1984)Nonsteroidal anti-inflammatory drugs and immunologic function: overview of the European experience.
Am J Med
(1984)- et al.
Diffuse pulmonary injury associated with gold treatment.
N Engl J Med
(1976) - et al.
Pulmonary fibrosis associated with hypersensitivity to gold salts.
Br Med J
(1976) - et al.
Pneumonitis caused by gold salt therapy: evidence for the role of cell-mediated immunity in its pathogenesis.
Am Rev Respir Dis
(1980) - et al.
Life-threatening hypersensitivity to sulindac.
JAMA
(1980)